Submit a Manuscript to the Journal

Therapeutics and Clinical Risk Management

For an Article Collection on

Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome

Manuscript deadline
31 December 2024

Cover image - Therapeutics and Clinical Risk Management

Article collection guest advisor(s)

Prof. Manfredi Rizzo, University of Palermo, Italy
[email protected]

Dr. Dimitrios Patoulias, Aristotle University of Thessaloniki, Greece
[email protected]

Submit an ArticleVisit JournalArticles

Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome

Cardio-Kidney-Metabolic (CKM) syndrome has been recently recognized by the American Heart Association (AHA) as the close interplay between cardiovascular disease (CVD), chronic kidney disease (CKD) and metabolic risk factors, mainly diabetes mellitus and obesity. CKM syndrome has attracted scientific attention due to its growing prevalence worldwide, reaching pandemic dimensions, whereas, several newer and novel therapeutic agents, targeting various pathophysiological aspects of CKM syndrome, have emerged over the last years, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, incretin-based agents, tirzepatide, finerenone, and many other. The aim of this Article Collection is to gather scientific evidence regarding the impact of newer therapeutic agents on various components of CKM syndrome, as adjunct to established treatment options.

According to recent evidence from the United States, approximately 90% of the U.S. population appear to be at some stage of CKM syndrome. In addition, CVD still represents one of the leading causes of death worldwide, whereas it is also associated with substantial morbidity and healthcare costs. Based on evidence from the European Union, in 2021, more than 280 billion euros were spent for the therapeutic management of patients with some form of CVD, which was the leading cause of death, followed by cancer. Since there is an increasing prevalence of dysmetabolism, including diabetes mellitus and obesity, it is of utmost importance to early identify specific patients’ phenotypes and apply appropriate therapeutic strategies against the progression of CKM syndrome, to minimize relevant morbidity and of course mortality.

Sub-topics of specific interest

  • Older antidiabetic drug classes and CKM syndrome
  • SGLT-2 inhibitors and CKM syndrome
  • Incretin-based agents and CKM syndrome
  • Novel anti-obesity drugs and cardio-renal implications
  • RAAS blockers and CKM syndrome
  • Implications of artificial intelligence as a therapeutic tool in CKM syndrome
  • Novel technologies in the therapeutic management of patients with CKM syndrome

Preferred article types

  • Original articles
  • Systematic reviews and/or meta-analyses
  • Narrative reviews

Keywords

  • Cardiovascular disease
  • Chronic kidney disease
  • Diabetes mellitus
  • Obesity
  • Therapeutics

­­All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31 December 2024.

Please contact Zhiyuan Zhang at [email protected] with any queries and discount codes regarding this Article Collection.


Guest Advisors

Prof. Manfredi Rizzo is Professor of Internal Medicine at the School of Medicine, University of Palermo, Italy with a joint position as Head of the Unit of Diabetes and Cardiovascular Prevention at the University Hospital (Policlinic) of Palermo. He is also the Head of the Cardiometabolic Research Laboratory of the Department of Internal Medicine at the University of Palermo.

Dr. Dimitrios Patoulias, MD, MSc, PhD, FRCP(Lond), FNEASO, FNSCOPE, is an Internal Medicine physician with special interest in Cardiometabolic Medicine. He has authored or co-authored >250 peer-reviewed articles indexed in PubMed database, mainly in the field of Cardiometabolic Medicine. His current h-index is 18.

Benefits of publishing open access within Taylor & Francis

Global marketing and publicity, ensuring your research reaches the people you want it to.

Article Collections bring together the latest research on hot topics from influential researchers across the globe.

Rigorous peer review for every open access article.

Rapid online publication allowing you to share your work quickly.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.